This aligns with previous studies reporting reduced PSD‐95 and synaptic proteins in SCZ brains.[66, 67, 68] miR‐485‐5p, a brain‐enriched miRNA, has been implicated in synaptic plasticity[69] and neurodegeneration.[23, 70] Our finding that miR‐485‐5p directly targets ARHGAP8 aligns with studies showing that miR‐485‐5p overexpression in the hippocampus rescues synaptic deficits in epilepsy models.[69] This dual‐target strategy leverages the bidirectional effect of ceRNA networks, providing a blueprint for RNA‐based therapies in SCZ and related synaptopathies. Here, DLG4 is linked to epilepsy.